Physician profile
Mark Makar
NPI 1265059653
$4,475.07
in general payments reported to CMS, 2019-2025
17 companies · $2,271 in 2025
The $2,271 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $550 · 2024: $1,654 · 2025: $2,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,475.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,059.83 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,033.28 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $808.49 | 2023-2025 | |
| Exact Sciences Corporation | $290.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $261.58 | 2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $217.04 | 2023-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $146.36 | 2024 | |
| Phathom Pharmaceuticals, INC. | $121.87 | 2024-2025 | Voquezna |
| Verona Pharma, INC. | $121.44 | 2025 | Ohtuvayre |
| Amgen INC. | $97.04 | 2024-2025 | Otezla, Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $78.76 | 2024 | Eliquis, Camzyos |
| Pfizer INC. | $68.17 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $48.64 | 2024-2025 | Gardasil 9, Capvaxive, Proquad |
| Axsome Therapeutics, INC. | $40.65 | 2025 | Auvelity |
| Esperion Therapeutics, INC. | $39.50 | 2025 | Nexletol |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.87 | 2024 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $13.88 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Makar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.